ORAMED PHARMACEUTICALS INC. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2011 to 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Oramed Pharmaceuticals Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2011 to 2023.
- Oramed Pharmaceuticals Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2024 was $10.8M.
- Oramed Pharmaceuticals Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $5.09M.
- Oramed Pharmaceuticals Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$37.7M.
- Oramed Pharmaceuticals Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$11.5M, a 18.1% increase from 2019.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)